SCREENING AND CONFIRMATORY TESTING OF A COUNTERFEIT M-30 PILL ADULTERATED WITH XYLAZINE

Significance of the Topic

The emergence of counterfeit prescription pills adulterated with veterinary sedatives poses a growing threat to public health and forensic toxicology. Xylazine, originally developed for animal use, has been increasingly detected in illicit drug mixtures and linked to overdose fatalities. Rapid and reliable analytical methods are essential to screen and confirm the presence of such adulterants in seized samples, ensuring accurate intelligence for law enforcement and healthcare responders.

Objectives and Study Overview

This study illustrates a comprehensive workflow for both screening and confirmatory analysis of a counterfeit M-30 pill adulterated with xylazine. The pill, resembling oxycodone, was seized by the San Diego County Sheriff’s Crime Laboratory and provided to Waters™ for method demonstration. The goals were to (1) rapidly detect a broad range of illicit compounds, (2) confirm and semi-quantify target analytes, and (3) validate performance using high-resolution and tandem mass spectrometry.

Methodology and Instrumentation

Sample Preparation:

• The pill was shaved to a fine powder, 1 mg was dissolved in 1 mL ethanol, and filtered (0.2 µm PTFE).
• Aliquots were diluted with aqueous methanol for screening and further diluted for confirmation.

Screening Analysis:

• ACQUITY UPLC I-Class PLUS FTN System coupled to ACQUITY RDa Detector
• Positive ionization, full-scan accurate mass (50–2000 m/z) with fragmentation, 9.5 min gradient, 10 µL injection
• Data processed via waters_connect software against a custom library of 400 compounds

Confirmatory Analysis:

• Xevo TQ-Absolute MS with ACQUITY UPLC I-Class PLUS FTN
• MRM mode with quantitative/qualitative transitions, 4.5 min run, 1 µL injection
• Five-point external calibration (0.5–100 ng/mL or 1–250 ng/mL)
• Data processed with TargetLynx XS

Main Results and Discussion

Screening detected fourteen presumptive positives including xylazine, multiple fentanyl analogs (fentanyl, acetylfentanyl, O(p)-fluorofentanyl, despropionyl para-fluorofentanyl), 4-ANPP isomers, caffeine, acetaminophen, lidocaine, procaine, tramadol and European analgesic metabolites. High-resolution exact mass (<2 ppm error) and retention times matched library criteria. Confirmatory analysis semi-quantified eleven compounds:

• Xylazine at 913 ng/mL (R²>0.995)
• Fentanyl at 7444 ng/mL
• Several analogs and common adulterants above and below 50 ng/mL

Benefits and Practical Applications

This dual approach provides rapid, high-confidence screening for a broad spectrum of illicit substances and reliable confirmation with quantitation. Laboratories can adopt this workflow to enhance forensic drug profiling, optimize turnaround times in seized sample analysis, and support public health monitoring of emerging adulterants.

Future Trends and Opportunities

• Expansion of high-resolution libraries to include novel psychoactive substances and synthetic opioids
• Integration of automated data processing and AI-driven identification workflows
• Miniaturized or field-deployable LC-MS platforms for on-site drug screening

Conclusion

A validated workflow combining UPLC-RDa screening and UPLC-TQ confirmation successfully identified and quantified xylazine and multiple fentanyl analogs in a counterfeit M-30 pill. The method offers forensic laboratories a robust, efficient solution to counter evolving drug adulteration challenges.

Reference

1. U.S. Drug Enforcement Administration. The Growing Threat of Xylazine and its Mixture with Illicit Drugs. Accessed May 31, 2023.